Our research and development group is organised with key senior managers leading the following areas of the investigational product lifecycle:
- Innovation and concept
- Product development
- Target product profiling
- Process development and technology transfer
- Method development & validation
- Regulatory affairs and filing strategy
- Clinical sciences and operations
- Scientific communications
We have a range of licensed products, named patient products and investigational products in clinical development. We have recently made key appointments in our clinical teams to accommodate the increase in clinical development in both European and US markets.
Murray Skinner leads our R&D team as company CSO and we have recently made key appointments in the area of Clinical Development to enable completion of our ambitious global R&D programme.
Our early phase (phase I/II) clinical development programme is led by Head of Clinical Sciences Simon Piggott.
Our late phase (phase II/III) clinical development programme is led by Head of Clinical Operations Denise Lee.
The recent appointment of Simon Piggott and planned growth within Simon and Denise’s teams will allow us to realise our ambitious plans for clinical development in Europe.
Our US programme is led by Clinical Director Pieter-Jan de Kam. Pieter-Jan is responsible for clinical development of products for the US market.
Our current portfolio includes marketed and named patient products.Product development
View the Groups recent publications and posters to learn about our commitment to allergy.Publications and posters
Our research and development teams comprise Clinical Development, Product Development and Method Development spread over several sites across Europe and the USA.Class-leading immunotherapies